Drug in CD in liposome for targeted delivery of anti-tubercular drugs
Nkanga and Krause have published in Nature Scientific Reports their recent development of a novel anti-tubercular drug delivery system. Isoniazid-hydrazone-phthalocyanine
Category: Pharma applications
Efficient Grafting of Cyclodextrin to Alginate and Performance of the Hydrogel for Release of Model Drug
Controlling the rate of release of molecules from a hydrogel is of high interest for various drug delivery systems and
17th Annual Congress of International Drug Discovery Science and Technology
The 17th Annual Congress of International Drug Discovery Science and Technology-2019 (IDDST-China 2019) will take place in Nanjing, China on
International Pharmacology and Pharmaceutical Sciences Conference
The “International Pharmacology and Pharmaceutical Sciences Conference (OLCPPSC-2019)” which is going to be held during November 14-15, 2019 at Venice, Italy.
New clinical trial with cyclodextrins on hernia treatment
A new clinical trial with a rather innovative use of cyclodextrins is about to start shortly, although the recruitment has
AAPS 360 2019
The annual meeting of American Pharmaceutical Society will be held on November 3-6, 2019 in San Antonio, Texas. The aim
2019 International Conference on Biotechnology and Bioengineering
2019 International Conference on Biotechnology and Bioengineering (9th ICBB, 2019) will be held in Poznan, Poland on September 25-28, 2019. The
Folate-Decorated Amphiphilic Cyclodextrins as Cell-Targeted Nanophototherapeutics
The group of Prof. Mazzaglia published on a ternary nanoassembly (SAP) composed of nonionic amphiphilic β-cyclodextrins (amphiphilic CD) incorporating pheophorbide
Polymeric Nanoparticles as Promising Tool for Anti-cancer Therapeutics
Polymeric Nanoparticles as Promising Tool for Anti-cancer Therapeutics (edited by Prashant Kesharwani, Kishore Paknikar and Virendra Gajbhiye) and published by
Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol